To confirm these results, we used a dual ISH and immunohistochemistry approach to validate RIPK1 mRNA is expressed in IBA1+ microglia and GFAP+ astrocytes at similar levels in NAWM controls and progressive MS samples (Figures 1H and S1I-S1K). The gene discussed is GFAP; the disease is myeloid sarcoma.